scPharmaceuticals Inc. (NASDAQ:SCPH) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET
Company Participants
Nick Colangelo – Investor Relations
John Tucker – Chief Executive Officer
Steve Parsons – Senior Vice President of Commercial
Rachael Nokes – Chief Financial Officer
Conference Call Participants
Anupam Leesy – Leerink Partners
Stacy Ku – TD Cowen
Douglas Tsao – H.C. Wainwright
Chase Knickerbocker – Craig-Hallum
Operator
Good afternoon, and welcome to scPharmaceuticals’ Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we will hold a question-and-answer session. [Operator Instructions] As a reminder, today’s conference call is being recorded.
I would now like to turn the conference call over to Nick Colangelo, Investor Relations, to cover forward-looking statements. Nick, please go ahead.
Nick Colangelo
Thank you, Operator. Before beginning today’s earnings call, we would like to highlight the following forward-looking statements. All statements on this conference call, other than historical facts, are forward-looking statements within the meaning of the federal securities laws, including, but not limited to, statements regarding scPharmaceuticals expected future financial results, management’s expectations and plans for the business, the ongoing commercialization and marketing of FUROSCIX, and other regulatory approvals of FUROSCIX.
The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project, and other similar expressions are used typically to identify such forward-looking statements. These forward-looking statements are not guarantees of the future performance. It may involve and are subject to certain risks and uncertainties and other crucial factors that may affect scPharmaceuticals’ business, financial condition, and other operating results.
These include, but are not limited to, the risk factors and other qualifications contained in scPharmaceuticals’ annual report on Form 10-K, quarterly reports on Form 10-Q and other reports filed by the company with the SEC to which your attention is directed. Actual outcomes
